Cardiac Disease in Adolescents With Delayed Diagnosis of Vertically Acquired HIV Infection by Miller, RF et al.
H I V / A I D S M A J O R A R T I C L E
Cardiac Disease in Adolescents With Delayed
Diagnosis of Vertically Acquired HIV Infection
Robert F. Miller,1,3 Juan P. Kaski,2,4 James Hakim,6 Jonathan Matenga,6 Kusum Nathoo,7 Shungu Munyati,8
Sujal R. Desai,5 Elizabeth L. Corbett,3,8,9 and Rashida A. Ferrand3,8
1Research Department of Infection and Population Health, Institute of Epidemiology and Healthcare, and 2Institute of Cardiovascular Science,
University College London, 3Clinical Research Department, London School of Hygiene and Tropical Medicine; 4Department of Cardiology, Great Ormond
Street Hospital for Children, and 5Department of Radiology, King’s College London, King’s Health Partners, King’s College Hospital NHS Foundation
Trust, London, United Kingdom; 6Department of Medicine and 7Department of Paediatrics, University of Zimbabwe, and 8Biomedical Research and
Training Institute, Harare, Zimbabwe; and 9Malawi-Liverpool Research Program, University of Malawi, Blantyre
Background. At least one-third of human immunodeﬁciency virus (HIV)–infected infants survive to adoles-
cence even without antiretroviral therapy (ART), but are at high risk of complications including cardiac disease.
We investigated the characteristics of cardiac disease among adolescents with HIV infection diagnosed in late
childhood who were receiving ambulatory HIV care in Harare, Zimbabwe.
Methods. Consecutive adolescents with vertically acquired HIV attending 2 HIV outpatient treatment clinics
were studied. Assessment included clinical history and examination, and 2-dimensional, M-mode, pulsed- and
continuous-wave Doppler echocardiography.
Results. Of 110 participants (47% male; median age, 15 years; interquartile range, 12–17 years), 78 (71%)
were taking ART. Exertional dyspnea, chest pain, palpitations, and ankle swelling were reported by 47 (43%), 43
(39%), 10 (9%), and 7 (6%), respectively. The New York Heart Association score was ≥2 in 41 participants (37%).
Echocardiography showed that 74 participants (67%) had left ventricular (LV; septal and/or free wall) hypertrophy
and 27 (24%) had evidence of impaired LV relaxation or restrictive LV physiology. The estimated pulmonary
artery systolic pressure (ePASP) was >30 mm Hg in 4 participants (3.6%); of these 2 also had right ventricular
(RV) dilatation. Another 32 participants (29%), without elevated ePASP, had isolated RV dilatation.
Conclusions. A signiﬁcant burden of cardiac disease was seen among adolescents with vertically acquired
HIV infection. More than half were asymptomatic yet had signiﬁcant echocardiographic abnormalities. These
ﬁndings highlight the need to screen this population in order to better deﬁne the geography, natural history,
etiopathogenic mechanisms, and management (including the timing and choice of optimal therapeutic ART and
cardiac drug interventions) to prevent development and/or progression of HIV-associated cardiac disease.
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Of the current estimated 2.5 million global human
immunodeﬁciency virus (HIV) infections among
children (age 0–14 years) >90% have occurred in
sub-Saharan Africa, predominantly owing to mother-
to-child transmission [1]. At least one-third of HIV-
infected infants have slow-progressing disease with a 50%
probability of surviving to adolescence even without HIV
treatment [2–4]. An estimated 3% of all 10-year-olds
living in Southern Africa are estimated to be “slow pro-
gressors,” the majority undiagnosed [4, 5]. These regional
estimates of the burden of HIV infection reﬂect the high
HIV prevalence rates among pregnant women during
the 1990s and the lack of interventions to prevent
mother-to-child transmission at that time. These children
typically present to clinicians in older childhood and
early adolescence with pronounced advanced immuno-
suppression or with longstanding chronic complications
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typical of pediatric HIV/AIDS, notably lung and cardiac disease
[6, 7]. We have recently described the high burden of chronic
lung disease, due to previously undescribed small airway disease,
among adolescents with vertically acquired HIV infection who
were receiving ambulatory HIV care at 2 public sector hospitals
in Harare, Zimbabwe [6], and in a previous study of hospitalized
HIV-infected adolescents we also recorded cardiac disease (in-
cluding dilated cardiomyopathy) in 12% [7].
Cardiac disease is well described in HIV-infected infants and
young children in both high- and low-resource settings [8–16].
Frequently described abnormalities include left ventricular (LV)
diastolic dysfunction, dilated cardiomyopathy, increased LV wall
thickness or mass, decreased LV fractional shortening, and peri-
cardial effusion [8–16]. By contrast, data on cardiac abnormalities
among HIV-infected older children and adolescents are scarce.
The aim of the present study was to describe the clinical
characteristics and echocardiographic features of cardiac
disease among the previously described cohort of adolescents
with vertically acquired HIV infection receiving outpatient
HIV care in Harare, Zimbabwe [6].
METHODS
Patients
Consecutive patients aged 10 to 19 years attending the HIV
outpatient clinics at Harare Central and Parirenyatawa Hospi-
tals, Harare, were enrolled into a study to investigate lung and
cardiac disease [6]. Exclusion criteria including having HIV in-
fection that was probably horizontally acquired, residing outside
of Harare, being too ill to participate (ie, needing immediate
hospitalization), being pregnant, or having pulmonary Kaposi
sarcoma, recently diagnosed tuberculosis, or an intercurrent
acute lower respiratory tract infection. HIV infection was con-
sidered vertically acquired if the following speciﬁc criteria were
present: maternal and/or sibling death or known maternal HIV
infection as well as no history of sexual debut or blood transfu-
sion, history of frequent early childhood infections, or stunting
or pubertal delay, as described elsewhere [6, 17].
Data Collection
Participant demographics, stage of HIV infection (using the
World Health Organization [WHO] adult classiﬁcation) [18],
receipt of antiretroviral therapy (ART), and symptoms (includ-
ing New York Heart Association [NYHA] functional score)
were recorded on a standard proforma. All participants under-
went a clinical examination including height and weight mea-
surement, recording of heart rate, pulse oximetry (arterial
oxygen saturation at rest and after exercise) and presence of
ankle edema. All participants had a CD4 cell count mea-
sured (CyFlow counter; Partec) and underwent transthoracic
echocardiography. The z scores for height and weight for age
were calculated using British 1990 growth reference curves [19].
Echocardiographic Examination
Transthoracic echocardiography was done using a Toshiba
Xario machine (Toshiba Medical Systems) with a 3.0-MHz
transducer. Consensus criteria for echocardiographic measure-
ments, based on recommendations of the American Society of
Echocardiography [20, 21] were developed by the 2 study car-
diologists ( J. H. and J. M.) in joint sessions on 10 adolescent
patients (who were not subsequently included in the present
study). A standard protocol was used with 2-dimensional,
M-mode, pulsed- and continuous-wave Doppler echocardiog-
raphy and color ﬂow mapping. Scanning was done in the left
parasternal long and short axes, apical 2-chamber, 4-chamber,
and subcostal views [21]. The measurement of chamber di-
mensions, estimation of ejection fraction, and fractional short-
ening were performed according to recommendations of the
American Society of Echocardiography [20]. The peak estimat-
ed pulmonary arterial systolic pressure (ePASP) was derived
by calculating the systolic pressure gradient between the right
ventricle and right atrium by the maximum velocity of the tri-
cuspid regurgitant jet, using the modiﬁed Bernoulli equation,
and then adding 10 mm Hg unless the right atrial pressure
was judged to be high (in which case 15 mm Hg was added)
or low (in which case 5 mm Hg was added) [22]. For all mea-
surements, the ﬁnal value was the average of measurements
performed in 3 sequential cardiac cycles.
Statistical Analysis
Stata software (version 10.0; StataCorp) was used for analyses.
Echocardiographic parameters were expressed as a deviation
from the body surface area–corrected mean (z scores), based
on published normal values published elsewhere [23, 24].
The following deﬁnitions were used: LV dilatation, LV end-
diastolic dimension z score >2; LV hypertrophy, maximal wall
thickness (interventricular septum or LV posterior wall
[LVPW]) z score >2; “concentric” LV hypertrophy, both inter-
ventricular septum and LVPW z scores >2; left atrial (LA) di-
latation, LA z score >2; LV systolic impairment, fractional
shortening <25% or ejection fraction <50%; LV diastolic dys-
function, mitral inﬂow E/A ratio (the ratio between peak early
[E] and late diastolic [A] transmitral ventricular ﬁlling veloci-
ties) <1, or >2; right ventricular (RV) dilatation, RV end-
diastolic dimension z score >2; and pulmonary hypertension,
ePASP >30 mm Hg.
The association between clinical variables (sex, age, height for
age, weight for age, and body mass index, WHO stage, CD4 cell
count, and duration and type of ART [zidovudine and/or a pro-
tease inhibitor–containing regimen]) and speciﬁc echocardio-
graphic abnormalities (LV hypertrophy, LV diastolic dysfunction,
HIV/AIDS • CID 2013:56 (15 February) • 577
and RV dilatation) were investigated using the χ2 test for categor-
ical variables and the Mann-Whitney U test for variables that
were not normally distributed.
Variables that showed an association at a signiﬁcance level
of P < .1 were analyzed using multivariate logistic regression
analysis; differences were considered signiﬁcant at P < .05.
Ethics
All participants gave their assent to participate in the study.
Written informed consent in either English or Shona was also
obtained from the guardians of all participants. Ethical ap-
proval was obtained from the Medical Research Council of
Zimbabwe, the Biomedical Research and Training Institute In-
stitutional Review Board, Harare, and the London School of
Hygiene and Tropical Medicine Ethics Committee.
RESULTS
Baseline Clinical Characteristics
Baseline demographic and clinical characteristics of 110 par-
ticipants (median age, 15 years; interquartile range [IQR],
12–17 years; 47% male) are shown in Table 1. Seventy-eight
(70.9%) were taking ART, for a median duration of 20 months
(IQR, 5–40 months). The median CD4 cell counts did not
differ between those taking ART and those who were not (402
[IQR, 196–590] vs 351 [77–535] cells/µL; P = 0.16). Of those
receiving ART, the regimen included zidovudine in 13, of
whom 6 also received a protease inhibitor.
No participants were cigarette smokers, and none were re-
ceiving angiotensin-converting enzyme inhibitors, β-blockers,
calcium channel blockers, digoxin, diuretics, or vasodilators.
Sickle cell disease and congenital and rheumatic heart disease
were excluded in all participants: 1 had a previous diagnosis of
dilated cardiomyopathy. Forty-one participants (37%) were
symptomatic (NYHA score ≥2), and at rest 31 (28%) were ta-
chycardic (heart rate >100 beats per minute) and 16 (14.5%)
were hypoxemic (arterial oxygen saturation <92%).
Echocardiographic Findings
Echocardiographic ﬁndings in the 110 participants are sum-
marized in Figure 1 and Table 2.
LV Dilatation and Systolic Impairment
In total, 12 participants (10.9%) had LV dilatation (n = 8
[7.3%]) and/or systolic impairment (n = 6 [5.5%]; Table 2). Of
Table 1. Baseline Demographic and Clinical Characteristics
Among 110 Adolescents With Vertically Acquired Human Immu-
nodeﬁciency Virus Infection
Characteristic No. (%)
Age, y
<13 28 (25.5)
13–15 30 (27.2)
16–19 52 (47.3)
Male sex 52 (47)
Height-for-age z score, median (IQR) −2.22 (−3.05 to −1.3)
Weight-for-age z score, median (IQR) −1.84 (−3 to −0.94)
BMI z score, median (IQR) −0.69 (−1.81 to 0.11)
Taking ART 78 (71)
Regimen
2 NRTIs + 1 NNRTI 70 (63.6)
2 NRTIs + PI 6 (5.5)
Not known 2 (1.9)
CD4 count, median (IQR), cells/µL 384 (171–578)
Symptoms and signs
Shortness of breath on exertion 47 (43)
Chest pain on exertion 43 (39)
Palpitations 10 (9)
Ankle swelling 7 (6)
NYHA functional classification
I 69 (63)
II 18 (16)
III 21 (20)
IV 2 (2)
Tachycardia at rest (HR >100/min) 31(28)
SaO2 at rest <92% 16 (14.5)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HR, heart
rate; IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase
inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; NYHA, New York
Heart Association; PI, protease inhibitor; SaO2, arterial oxygen saturation.
Figure 1. Prevalence of echocardiographic ﬁndings among 110 adoles-
cents with vertically acquired human immunodeﬁciency virus infection.
Unless otherwise speciﬁed, numbers represent numbers of adolescents
with ﬁnding. Abbreviations: ePASP, estimated pulmonary artery systolic
pressure; LVEDD, left ventricular end-diastolic dimension; LVMWT, left
ventricular maximum wall thickness; RVEDD, right ventricular end-
diastolic dimension; z, z score.
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these, 3 participants (2.7%) had LV end-diastolic dimension z
scores >3, and 3 (2.7%) with LV dilatation also had mild
mitral valve regurgitation (Figure 2). Seven participants (6.4%)
had a LV mass z score >2, including the 2 with both LV dila-
tation and systolic impairment.
LV Hypertrophy
A total of 74 participants (67.2%) had LV hypertrophy, with a
septal wall thickness z score >2 (n = 53 [48.1%]) or LVPW
thickness z score >2 (n = 48 [43.6%]); 27 (24.5%) had both
septal and LVPW thickness z scores >2 (“concentric” LV hy-
pertrophy). Using a more conservative deﬁnition of LV hyper-
trophy (LV maximal wall thickness z score >3), 48 (43.6%) of
participants had LV hypertrophy (septal wall thickness z score
>3, n = 35 [31.8%]; LVPW thickness z score >3, n = 17
[15.5%]), including 7 (6.4%) with concentric LV hypertrophy.
LV Diastolic Dysfunction
Four participants (3.6%) had a mitral inﬂow E/A ratio <1, im-
plying impaired LV relaxation, whereas 23 (20.9%) had E/A
ratios >2, implying restrictive LV physiology. Of these 23 par-
ticipants, 3 had concomitant LA dilatation. Another 5 partici-
pants had LA dilatation with a normal mitral E/A ratio; 2 had
concomitant LV dilatation, and the remaining 3 had evidence
of LV hypertrophy.
Pulmonary Hypertension
A tricuspid valve regurgitant jet was present in all individuals,
allowing Doppler-derived ePASP to be calculated. Eight par-
ticipants (7.3%) had an ePASP >25 mm Hg. Of these, 4 (3.6%)
had an ePASP >30 mm Hg. In 2 (1.8%), this was associated
with RV dilatation, including 1 individual with concomitant
LV dilatation.
RV Dilatation
Another 32 individuals (29%), without an elevated ePASP,
had isolated RV dilatation, including 10 (9.1%) with an RV
end-diastolic dimension z score >3.
Other Abnormalities
None of the 110 individuals had intracavitary thrombus, peri-
cardial thickening, or an effusion.
Clinical Correlates of Cardiac Dysfunction
In univariate analysis, female sex, stunting (height-for-age z
score >2), and CD4 cell count were associated with LV dia-
stolic dysfunction. Participants’ body mass index, CD4 cell
count, and duration of ART were associated with LV hypertro-
phy, and duration of ART was associated with RV dilatation.
At multivariate analysis, only female sex and stunting re-
mained signiﬁcantly associated with LV diastolic dysfunction,
and duration of ART remained signiﬁcantly associated with
RV dilatation; no signiﬁcant associations remained for LV hy-
pertrophy. Multivariate analysis showed that female study par-
ticipants and those with stunting were more likely to have
LV diastolic dysfunction; (odds ratio, 2.86 [95% conﬁdence
interval, 1.05–7.69] and 3.70 [1.41–10.0], respectively. RV
dilatation was associated with duration of ART, those with a
>12-month exposure to ART had a higher odds of RV dilata-
tion than those taking ART for a shorter period (odds ratio,
3.48; 95% conﬁdence interval, 1.04–11.65). Of note, there was
no association between any echocardiographic abnormality
and participants’ age, weight for age (wasting), body mass
index, WHO stage, CD4 cell count, NYHA classiﬁcation, or
receipt of a zidovudine- or protease inhibitor–containing
regimen of ART.
Table 2. Echocardiographic Characteristics Among 110 Adoles-
cents With Vertically Acquired HIV Infection
Measurement Result, Median (IQR) z Score, Median (IQR)
RVEDD, mm 15.0 (12.6–17.5) +1.14 (+0.09 to 2.17)
LVEDD, mm 38.7 (34.5–42.5) −0.48 (−1.47 to 0.34)
LVESD, mm 24.1 (21.3–26.9) −0.81 (−1.44 to 0.18)
IVS, mm 8.1 (6.7–9.6) +1.89 (+0.64 to 3.39)
LVPW, mm 8.7 (7.1–9.9) +1.82 (+0.69 to 2.62)
LA, mm 25.3 (22.0–28.3) −0.18 (−1.39 to 0.80)
FS, % 38.7 (31.5–42.9) …
EF, % 69.3 (60.1–74.8) …
ePASP, mm Hg 12.0 (11.3–15.2) …
E/A ratio 1.58 (1.36–1.93) …
LV mass, g 85.7 (72.5–116.3) −0.14 (−1.06 to 0.87)
Abbreviations: E/A ratio, ratio between peak early (E) and late diastolic (A)
transmitral ventricular filling velocities; EF, ejection fraction; ePASP, estimated
pulmonary artery systolic pressure; FS, fractional shortening; IQR,
interquartile range; IVS, interventricular septum; LA, left atrial dimension; LV,
left ventricular; LVEDD, LV end-diastolic dimension; LVESD, LV end-systolic
dimension; LVPW, LV posterior wall; RVEDD, right ventricular end-diastolic
dimension.
Figure 2. Prevalence of left ventricular dilatation and systolic impair-
ment among 110 adolescents with vertically acquired human immunode-
ﬁciency virus infection. Unless otherwise speciﬁed, numbers represent
numbers of adolescents with ﬁnding. Abbreviations: EF, ejection fraction;
LVEDD, left ventricular end-diastolic dimension; z, z score.
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DISCUSSION
The major ﬁnding of this study was the signiﬁcant burden of
cardiac disease among HIV-infected adolescents with vertical-
ly acquired HIV infection receiving ambulatory HIV care.
Echocardiography showed that more than two-thirds of par-
ticipants had LV hypertrophy, with 24% having impaired LV
diastolic dysfunction and 4 participants (3.6%) having an el-
evated ePASP: furthermore, 29% of participants without an
elevated ePASP had RV dilatation. Of note, more than half
of participants were asymptomatic despite the high frequen-
cy of echocardiographic abnormalities. The ﬁnding of LV
hypertrophy should be interpreted with caution, because the
z scores were based on a predominantly white European
population and so may be overreported [23]. In addition, wall
thickness measurements were made using M-mode, which has
a lower spatial resolution than 2-dimensional imaging, and
may therefore overestimate the degree of hypertrophy.
However, even when a more rigorous cutoff of z score >3 was
used, >40% of participants had LV hypertrophy.
The surprising ﬁnding in the present study was that almost a
third of participants had RV dilatation, in the absence of an
elevated ePASP. The ﬁnding of RV dilatation and/or dysfunc-
tion in the present study may be a consequence of chronic lung
disease described elsewhere among this cohort of participants;
45% of whom had an forced expiratory volume in 1 second
<80% and 47% an abnormal chest radiograph. The most likely
cause was small airway disease, probably constrictive oblitera-
tive bronchiolitis, with or without bronchiectasis [6].
RV hypertrophy and dilatation, ascribed to cor pulmonale,
has previously been reported in 48% of symptomatic HIV-
infected children (median age, 9 months) in Zimbabwe [25].
RV dilatation has also been described in HIV-infected chil-
dren and adolescents in studies from both Africa and the
United States [14, 26]; in a pediatric study from Uganda, par-
ticipants had a mean age of 6.8 years, and RV dilatation was
more common among those with advanced HIV disease [14].
Neither of these studies describe coexisting pulmonary disease
[14, 26]. The prospective, longitudinal P2C2 HIV study does
not speciﬁcally describe RV size or function [8–12]. Alterna-
tively, it might be postulated that HIV-infected individuals in
this geographic setting have either an associated underlying
genetic predisposition to dilated cardiomyopathy [27, 28] or
that cofactors might be important, such as cytomegalovirus,
coxsackie, adenovirus, or parvovirus infection [29] or dietary
factors, including selenium deﬁciency [30]. These potential co-
factors were not assessed in the present study.
Our study found no evidence of associations between echo-
cardiographic evidence of LV hypertrophy, LV diastolic dys-
function, and RV dilatation and many clinical variables,
including participants’ age, “wasting,” body mass index, NYHA
classiﬁcation, CD4 cell count, or receipt of an zidovudine- and/
or protease inhibitor–containing regimen of ART. However,
LV diastolic dysfunction seemed to be associated with female
sex and with stunting, and RV dilatation with receipt (but not
type) of ART for ≥12 months. These ﬁndings are similar to
those from a study of HIV-infected children (median age, 36
months) from Thailand, which found that echocardiographic
evidence of LV diastolic dysfunction did not correlate with par-
ticipants’ age, clinical symptoms and signs, nutritional status,
or HIV stage [16]. By contrast another study of HIV-infected
children (mean age, 6.8 years), performed in Kampala,
Uganda, showed HIV stage was associated with echocardio-
graphic evidence of LV diastolic dysfunction, but not with LV
hypertrophy or RV dilatation: other clinical variables, including
wasting, stunting, NYHA classiﬁcation, and participants’
receipt of ART, were not recorded [14].
Another study from Lagos, Nigeria, showed no correlation
between echocardiographically determined LV hypertrophy
and LV systolic and diastolic dysfunction among HIV-infect-
ed children (median age, 44.2 months) and participants’ age,
sex, or HIV stage; however these echocardiographic abnor-
malities were associated with receipt of ART [15]. Further-
more, in a study of HIV-infected children (mean age, 2.8
years) in Boston, Massachusetts, LV mass was reported to
have an inverse relationship with weight and height z scores
and arm muscle circumference [31]. The inconstant associa-
tions between clinical variables and echocardiographic ab-
normalities in these studies and in the present study
probably in part reﬂect differences in the demographics of
participants and in study design.
The underlying mechanism by which HIV induces cardiac
disease remains unclear. In a rodent model, the HIV protein
gp120 has been shown to exert a direct negative inotropic
effect on ventricular myocytes [32,] resulting in a selective
defect in the diastolic relaxation response to adrenergic stimu-
lation [33]. Defective adrenergic signaling is common to both
ischemic and nonischemic cardiomyopathy [34]. Most reports
describe HIV RNA and viral proteins predominantly in
cardiac interstitial macrophages and lymphocytes, rather than
in myocytes; however, a strong correlation between the extent
of simian immunodeﬁciency virus replication in myocardium
and diastolic dysfunction has been described in macaques
[35]. These data imply a direct pathogenic role for HIV or
viral proteins in causing myocardial dysfunction and suggest
that early intervention with ART may prevent HIV-cardiac
myocyte interaction, thus limiting myocardial HIV replication
and subsequent myocardial damage and preventing the subse-
quent development of HIV-associated cardiac disease [36].
Earlier diagnosis of HIV infection may be important for
preventing the development of symptomatic cardiac disease
and international recommendations, which currently do not
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support immediately starting ART in children with HIV infec-
tion diagnosed at age ≥2 years, need to take into account the
risk of developing cardiac disease and the potential for early
initiation of ART to prevent or to slow its progression [37].
Against this is evidence from the present study and another
study from Nigeria [15], which suggests that ART exposure
might increase the risk of cardiac disease [15]. These observa-
tions are consistent with reports of an association between LV
diastolic dysfunction and receipt of zidovudine [38], and
between both LV diastolic dysfunction and LV hypertrophy
and the duration of protease inhibitor–containing ART regi-
mens among HIV-infected adults [39], but they contrast with
a previous report from Uganda, wherein only 1 of 220 children
(21% aged 13–18 years) receiving a zidovudine-containing
ART regimen developed dilated cardiomyopathy [40].
The strengths of this study are its prospective design,
unselected patient recruitment, the exclusion of partici-
pants who were acutely unwell, and the systematic use of
2-dimensional, pulsed- and continuous-wave Doppler echo-
cardiography. Limitations include the cross-sectional study
design, the lack of local population reference values for de-
termining echocardiographic z scores, necessitating use of
US and European pediatric population-derived normal
values, and the lack of follow-up to correlate echocardio-
graphic ﬁndings and their associations with morbidity and
mortality, as demonstrated in other studies of HIV-infected
infants and children [8, 10]. Furthermore, diastolic function
was assessed only by using mitral inﬂow Doppler velocities;
further studies using pulmonary venous Doppler and tissue
Doppler imaging would provide a more accurate evaluation
of diastolic abnormalities in this population.
In conclusion, this study showed a signiﬁcant burden of
cardiac disease among adolescents with vertically acquired
HIV infection, almost three-quarters of whom were receiv-
ing ART. Echocardiographic abnormalities occurred in both
symptomatic and asymptomatic individuals. More than
two-thirds had echocardiographic evidence of LV hypertro-
phy, and a quarter had impaired LV diastolic dysfunction;
RV dilatation, probably secondary to chronic lung disease,
was present in more than a third. Further investigation of
the geographic distribution, the role of genetic, infectious,
and dietary factors in pathogenesis, the natural history, and
the histopathological correlates of cardiac disease among
HIV-infected adolescents in this setting is warranted to
focus healthcare resources and to identify appropriate pre-
ventative and treatment interventions.
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